4BIO Capital
Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code BioTherapeutics, a biotechnology company focused on the targeted delivery of genetic medicines for serious genetic diseases. McVeigh also serves as the Executive Chairman and Co-Founder of 4BIO Capital, and the Chairman of the Board for Genisphere, as well as holding various senior advisory and board roles in companies such as SciNeuro Pharmaceuticals, SG3 Ventures LLC, and UPMC Enterprises. With a robust background in the life sciences sector, McVeigh has successfully led multiple companies through strategic transitions and financings. McVeigh holds a Bachelor of Science in Accounting and Finance from La Salle University, an MBA from Villanova University, and additional credentials in pharmaceutical marketing and professional development from prestigious institutions.
This person is not in any teams
This person is not in any offices
4BIO Capital
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com